Masimo Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Los beneficios de Masimo han disminuido a una tasa media anual de -10.9%, mientras que en la industria Medical Equipment los beneficios crecieron en un 13.5% anualmente. Los ingresos han ido creciendo a una tasa media de 21.2% al año. La rentabilidad financiera de Masimo es de 6%, y sus márgenes netos son de 4%.

Información clave

-14.1%

Tasa de crecimiento de los beneficios

-14.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	8.9%
Tasa de crecimiento de los ingresos	20.6%
Rentabilidad financiera	5.8%
Margen neto	4.0%
Última actualización de beneficios	30 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Masimo: Promising Developments

May 12

Analyst Estimates: Here's What Brokers Think Of Masimo Corporation (NASDAQ:MASI) After Its First-Quarter Report

May 10

Baron Funds - Masimo Corp.: Can Potentially Double Our Investment

May 05

Is There Now An Opportunity In Masimo Corporation (NASDAQ:MASI)?

Apr 13

Masimo Corporation's (NASDAQ:MASI) Popularity With Investors Is Under Threat From Overpricing

Mar 28

Masimo Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 29

Estimating The Intrinsic Value Of Masimo Corporation (NASDAQ:MASI)

Feb 24

Masimo: Given The Lack Of Improvement In Revenues And Margins, It Is A Little Expensive

Feb 18

These 4 Measures Indicate That Masimo (NASDAQ:MASI) Is Using Debt Extensively

Feb 08

Earnings Tell The Story For Masimo Corporation (NASDAQ:MASI) As Its Stock Soars 27%

Dec 23

At US$112, Is It Time To Put Masimo Corporation (NASDAQ:MASI) On Your Watch List?

Dec 14

Masimo Corporation (NASDAQ:MASI) Shares Could Be 38% Below Their Intrinsic Value Estimate

Nov 09

Is Masimo Corporation (NASDAQ:MASI) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 02

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Masimo. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:MASI Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Mar 24	1,976	79	645	173
30 Dec 23	2,048	82	682	175
30 Sep 23	2,116	89	700	192
01 Jul 23	2,187	116	712	198
01 Apr 23	2,297	118	728	206
31 Dec 22	2,036	144	641	191
01 Oct 22	1,746	171	559	170
02 Jul 22	1,505	191	487	153
02 Apr 22	1,244	223	408	139
01 Jan 22	1,239	230	395	137
02 Oct 21	1,207	232	382	136
03 Jul 21	1,177	224	371	129
03 Apr 21	1,173	229	376	126
02 Jan 21	1,144	240	369	119
26 Sep 20	1,096	223	361	110
27 Jun 20	1,047	222	351	106
28 Mar 20	976	211	330	99
28 Dec 19	938	196	315	93
28 Sep 19	913	190	306	91
29 Jun 19	895	198	297	87
30 Mar 19	877	197	289	83
29 Dec 18	858	194	285	81
29 Sep 18	843	139	290	76
30 Jun 18	826	118	284	71
31 Mar 18	807	119	280	67
30 Dec 17	790	125	273	65
30 Sep 17	766	348	271	60
01 Jul 17	740	340	263	61
01 Apr 17	720	325	260	59
31 Dec 16	713	311	255	58
01 Oct 16	672	109	255	58
02 Jul 16	657	101	257	57
02 Apr 16	640	90	254	55
02 Jan 16	623	83	253	56
03 Oct 15	623	80	244	58
04 Jul 15	613	76	246	58
04 Apr 15	596	70	246	58
03 Jan 15	580	73	241	57
27 Sep 14	556	61	235	55
28 Jun 14	545	61	226	55
29 Mar 14	543	65	219	55
28 Dec 13	541	58	215	56
28 Sep 13	537	64	211	55
29 Jun 13	525	62	206	54

Ingresos de calidad: MASI tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(4%) de MASI son inferiores a los del año pasado (7.1%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de MASI han disminuido en un 10.9% al año en los últimos 5 años.

Acelerando crecimiento: MASI ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: MASI tuvo un crecimiento negativo de los beneficios (-43.3%) durante el año pasado, lo que dificulta la comparación con la media de la industria Medical Equipment (3.3%).

Masimo Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Masimo Corporation to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Masimo Corporation to Report Q4, 2023 Results on Feb 27, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Masimo Corporation to Report Q3, 2023 Results on Nov 07, 2023

Recent updates

Investor sentiment deteriorates as stock falls 16%

Masimo: Promising Developments

Analyst Estimates: Here's What Brokers Think Of Masimo Corporation (NASDAQ:MASI) After Its First-Quarter Report

Politan Capital Management Threatens Masimo Corporation with Legal Action

Masimo Corporation Provides Earnings Guidance for the Second Quarter 2024 and Updates Earnings Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Masimo Receives FDA Clearance for Stork Over-the-Counter (OTC) Baby Monitoring System

Baron Funds - Masimo Corp.: Can Potentially Double Our Investment

Lead Independent Director notifies of intention to sell stock

Masimo Corporation to Report Q1, 2024 Results on May 07, 2024

Is There Now An Opportunity In Masimo Corporation (NASDAQ:MASI)?

Masimo Corporation's (NASDAQ:MASI) Popularity With Investors Is Under Threat From Overpricing

Price target increased by 12% to US$135

Masimo Corporation Reaffirms Financial Guidance for the First Quarter and Fiscal Year 2024

Masimo Corporation(NasdaqGS:MASI) dropped from FTSE All-World Index (USD)

Masimo Corporation Provides Consolidated Earnings Guidance for the Fourth-Quarter and Full-Year 2024

Masimo Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 13% to US$128

Estimating The Intrinsic Value Of Masimo Corporation (NASDAQ:MASI)

Now 20% undervalued

Masimo: Given The Lack Of Improvement In Revenues And Margins, It Is A Little Expensive

Masimo Corporation Announces Board Changes

Masimo Announces the First FDA-Cleared “Over-The-Counter” Fingertip Pulse Oximeter

These 4 Measures Indicate That Masimo (NASDAQ:MASI) Is Using Debt Extensively

Masimo Corporation to Report Q4, 2023 Results on Feb 27, 2024

Masimo Announces Reinstatement of Import Ban on Infringing Apple Watches

Masimo Corporation Appoints Bob Chapek to the Board of Directors

Price target increased by 17% to US$108

Masimo Corporation Provides Consolidated Earnings Guidance for the Fourth Quarter and Full Year Ended December 30, 2023 and Full Year 2024

Earnings Tell The Story For Masimo Corporation (NASDAQ:MASI) As Its Stock Soars 27%

Masimo Receives FDA Clearance for Stork™ Baby Monitoring System

At US$112, Is It Time To Put Masimo Corporation (NASDAQ:MASI) On Your Watch List?

Masimo W1™ Medical Watch Receives FDA 510(K) Clearance for Over-The-Counter and Prescription Use

Consensus EPS estimates fall by 33%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Masimo Corporation (NASDAQ:MASI) Shares Could Be 38% Below Their Intrinsic Value Estimate

Price target decreased by 25% to US$96.14

Masimo Corporation Provides Earnings Guidance for the Fourth-Quarter and Full-Year 2023

Masimo Corporation to Report Q3, 2023 Results on Nov 07, 2023

Howard G. Smith Announces Securities Fraud Lawsuit Against Masimo Corporation

Masimo ORi™ Granted De Novo as the First and Only FDA-Cleared Noninvasive and Continuous Parameter to Provide Insight into Hyperoxia Under Supplemental Oxygen

Investor sentiment deteriorates as stock falls 16%

Is Masimo (NASDAQ:MASI) Using Too Much Debt?

Rosen Law Firm Announces the Filing of A Class Action Lawsuit on Behalf of Purchasers of Securities of Masimo Corporation

Consensus EPS estimates fall by 22%

Masimo Corporation Provides Earnings Guidance for the Third-Quarter and Full-Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There Now An Opportunity In Masimo Corporation (NASDAQ:MASI)?

Consensus EPS estimates fall by 25%

Consensus EPS estimates fall by 16%

Investor sentiment deteriorates as stock falls 24%

Price target decreased by 18% to US$155

Masimo Corporation to Report Q2, 2023 Results on Aug 08, 2023

Masimo Corporation Approves Board Elections

Masimo Corporation(NasdaqGS:MASI) dropped from Russell Small Cap Comp Value Index

Masimo Expands into the Personalized Hearables Market with Denon Perl™? True Wireless Earbuds, Featuring Masimo Aat™?

Here's Why Masimo (NASDAQ:MASI) Has A Meaningful Debt Burden

Politan Capital Management Sends a Letter to Shareholders of Masimo Corporation

Masimo Corporation Appoints Michelle Brennan as Sixth Director

Founder recently bought US$1.0m worth of stock

Politan Capital Management LP Posts Presentation to the Website

Politan Capital Releases Investor Presentation to Shareholders of Masimo Corporation

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Masimo Corporation Provides Earnings Guidance for the Full Year of 2023

Is It Too Late To Consider Buying Masimo Corporation (NASDAQ:MASI)?

Politan Capital Launches a Website in Connection with the Solicitation of Stockholders

Politan Capital Management Nominates Candidates for Masimo Board

Masimo (NASDAQ:MASI) Seems To Use Debt Quite Sensibly

Desglose de ingresos y gastos
Beta